We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.25
Bid: 19.50
Ask: 21.00
Change: 0.45 (2.31%)
Spread: 1.50 (7.692%)
Open: 19.95
High: 20.25
Low: 19.50
Prev. Close: 19.50
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Market Update

9 Jan 2023 07:00

RNS Number : 0109M
Iofina PLC
09 January 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

 

9 January 2023

 

Iofina Plc

("Iofina" or the "Company")

(AIM: IOF)

 

Q4 2022 Corporate Update

 Iodine Production Exceeds Forecast and IO#9 on Track

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides a brief update to the market regarding its activities during Q4 2022 (the "Period").

 

The Company continued to perform well during the Period, with Iofina Resources producing 139 metric tonnes (MT) of crystalline iodine from its IOsorb® iodine plants in Oklahoma, taking H2 2022 production to 282MT, which was ahead of the H2 upper forecast range of 255-275MT. In total, Iofina Resources produced 516 MT of crystalline iodine in 2022.

 

Demand for the Company's products remained strong in the Period, particularly crystalline iodine, our iodine-based biocide and our fluorine-based etchant gas. The iodine spot price moved up from $50/Kg at the start of the year and remained at approximately $70/Kg towards the end of 2022. The Company expects prices to stay at these levels as it moves through the early part of 2023, with global supply continuing to be tight. The Company's sales channels remain robust which is encouraging as the Company executes its iodine production expansion plans. 

 

Since signing the partner agreement for IO#9 during Q4 2022, Iofina Resources has worked quickly to bring materials and the construction team on-site to commence construction. The Company can confirm that work is progressing as anticipated and the new plant is on track with an expected start-up later in Q2 2023.

 

The Company is also continuing to work on other growth projects and is in advanced dialogue with potential oil and gas partners to supply brine water for its next plant, IO#10. Negotiations continue to progress positively in line with Iofina's commitment to achieve further expansion of iodine production capacity in the short term. The Company will provide a further update on developments in due course.

 

Looking ahead, Iofina Resources expects to produce 235-250 MT of crystalline iodine during H1 2023, solely from its five existing plants (H1 2022: 234 MT). The Company notes that H1 Iodine production has historically always been slightly lower compared to H2, and is primarily due to much lower temperatures in the winter months.

 

On the current timetable, IO#9 is expected to make an additional small contribution in H1, which the Company will update on once the plant is operational and production commences. Iofina anticipates the new plant will produce 100-150MT of crystalline iodine per annum.

 

Commenting, President and CEO of Iofina Dr. Tom Becker, stated: "Iofina had a strong end to 2022, with H2 iodine production surpassing our initial target and product sales remaining robust. As such, the Company is pleased with the expected outturn of its business in 2022.

 

"Looking ahead, with brine water supplies to our plants consistent and IO#9 on track for completion and start-up in Q2 2023, Iofina Resources will have the capacity to deliver a significant increase in crystalline iodine production going forward. Market dynamics for raw Iodine remain very favourable and coupled with the demand for our specialty products, the Board of Iofina is confident in the current outlook for the new year."

 

Construction images of IO#9:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Henry Fitzgerald-O'Connor/Patrick Dolaghan

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

 

Financial Adviser:

Kingsley Wilson

Chrystal Capital Partners LLP

Tel: +44 (0)20 7850 4761

 

Media Contact:

Charles Goodwin/Shivantha Thambirajah

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products will celebrate its 40th anniversary in 2023.

 

www.iofina.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSUFFWEDSEFF
Date   Source Headline
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.